US4618494A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Human Immune Factors and processes for their production and use
Assignee: Immunology Development Corp
•
Filing: 1984-07-20
•
Granted: 1986-10-21
•
Expires: 2004-07-20
Abstract
Abstract Type 1 Diabetes and other virus-induced or autoimmunological diseases are treated with Human Immune Factors. These Human Immune Factors are extracted from blood cells by activating said blood cells with human lymphoblastoid interferon-alpha or staphage lysate or other activator or combination of activators. Human Immune Factors are purified and made suitable for pharmaceutical use by isolating compounds with molecular weights between about 1,000 and about 25,000 daltons.
Inventors
- 👤 John W. Angers
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 22:51
CPC Classifications
A; A61; A61K; A61K35/00; A61K35/12; A61K35/14
Claims Analysis
Total Claims: 38
Claim 1
Independent Claim
107 words
A process for the preparation of a pharmaceutical composition for treating virus-induced and autoimmune diseases which comprises: a. removal of a blood sample from a donor, b. treatment of the blood sample with at least one effective activator selected from the group of interferons, bacterial antigens or both, to form an activated blood mixture, c. incubation of the activated blood mixture for a period sufficient for blood cells in the blood mixture to secrete extracts, d. purification of the extracts from the activated blood mixture by isolation of compounds in the activated blood mixture with molecular weights in the range from about 1,000 to about 25,000 daltons.
Claim 2
Dependent Claim
107 words
A process for the preparation of a pharmaceutical composition for treating virus-induced and autoimmune diseases which comprises: a. removal of a blood sample from a donor, b. treatment of the blood sample with at least one effective activator selected from the group of interferons, bacterial antigens or both, to form an activated blood mixture, c. incubation of the activated blood mixture for a period sufficient for blood cells in the blood mixture to secrete extracts, d. purification of the extracts from the activated blood mixture by isolation of compounds in the activated blood mixture with molecular weights in the range from about 1,000 to about 25,000 daltons.
Claim 3
Dependent Claim
15 words
The process of claim 1 wherein purification of the extracts is by dialysis and ultrafiltration.
Claim 4
Dependent Claim
17 words
The process of claim 1 wherein the activator is human lymphoblastoid interferon-alpha or staphage lysate or both.
Claim 5
Dependent Claim
17 words
The process of claim 1 wherein the incubation period is from about 24 to about 48 hours.
Claim 6
Dependent Claim
24 words
The process of claim 1 wherein purification isolates compounds having a molecular weight in the range of from about 1,000 to about 10,000 daltons.
Claim 7
Dependent Claim
14 words
The process of claim 1 which further comprises resuspending the purified extract in solution.
Claim 8
Dependent Claim
19 words
The process of claim 6 wherein the purified extract is resuspended in a solution of saline and ethyl alcohol.
Claim 9
Dependent Claim
24 words
The process of claim 6 wherein the purified extract is resuspended in approximately 0.14 molar saline solution containing approximately 1.75% ethyl alcohol by volume.
Claim 10
Dependent Claim
28 words
The process of claim 1 wherein the donor is a relative of the patient to be treated with the composition or is a member of the patient's household.
Claim 11
Dependent Claim
39 words
The process of claim 1 wherein purification isolates compounds having a molecular weight in the range of from about 1,000 to about 14,000 daltons, and wherein the activator is selected from the group of interferon, bacterial antigens, or both.
Claim 12
Dependent Claim
17 words
The process of claim 10 wherein the activator is human lymphoblastoid interferon-alpha or staphage lysate or both.
Claim 13
Dependent Claim
39 words
The process of claim 1 wherein purification isolates compounds having a molecular weight in the range of from about 14,000 to about 25,000 daltons, and wherein the activator is selected from the group of interferons, bacterial antigens, or both.
Claim 14
Dependent Claim
17 words
The process of claim 12 wherein the activator is human lymphoblastoid interferon-alpha or staphage lysate or both.
Claim 15
Dependent Claim
11 words
A pharmaceutical composition obtained by the process defined in claim 1.
Claim 16
Dependent Claim
11 words
A pharmaceutical composition obtained by the process defined in claim 3.
Claim 17
Dependent Claim
11 words
A pharmaceutical composition obtained by the process defined in claim 10.
Claim 18
Dependent Claim
11 words
A pharmaceutical composition obtained by the process defined in claim 11.
Claim 19
Dependent Claim
11 words
A pharmaceutical composition obtained by the process defined in claim 12.
Claim 20
Dependent Claim
11 words
A pharmaceutical composition obtained by the process defined in claim 13.
Claim 21
Dependent Claim
24 words
A method for the treatment of virus-induced or autoimmunological diseases which comprises administering an effective amount of the pharmaceutical composition defined in claim 14.
Claim 22
Dependent Claim
24 words
A method for the treatment of virus-induced or autoimmunological diseases which comprises administering an effective amount of the pharmaceutical composition defined in claim 15.
Claim 23
Dependent Claim
24 words
A method for the treatment of virus-induced or autoimmunological diseases which comprises administering an effective amount of the pharmaceutical composition defined in claim 16.
Claim 24
Dependent Claim
24 words
A method for the treatment of virus-induced or autoimmunological diseases which comprises administering an effective amount of the pharmaceutical composition defined in claim 19.
Claim 25
Dependent Claim
24 words
A method for the treatment of virus-induced or autoimmunological diseases which comprises administering an effective amount of the pharmaceutical composition defined in claim 18.
Claim 26
Dependent Claim
24 words
A method for the treatment of virus-induced or autoimmunological diseases which comprises administering an effective amount of the pharmaceutical composition defined in claim 19.
Claim 27
Dependent Claim
23 words
A method for the treatment of Type 1 Diabetes which comprises administering an effective amount of the pharmaceutical composition defined in claim 14.
Claim 28
Dependent Claim
23 words
A method for the treatment of Type 1 Diabetes which comprises administering an effective amount of the pharmaceutical composition defined in claim 15.
Claim 29
Dependent Claim
23 words
A method for the treatment of Type 1 Diabetes which comprises administering an effective amount of the pharmaceutical composition defined in claim 16.
Claim 30
Dependent Claim
23 words
A method for the treatment of Type 1 Diabetes which comprises administering an effective amount of the pharmaceutical composition defined in claim 17.
Claim 31
Dependent Claim
23 words
A method for the treatment of Type 1 Diabetes which comprises administering an effective amount of the pharmaceutical composition defined in claim 18.
Claim 32
Dependent Claim
23 words
A method for the treatment of Type 1 Diabetes which comprises administering an effective amount of the pharmaceutical composition defined in claim 19.
Claim 33
Dependent Claim
45 words
A method for the treatment of one or more virus-induced and autoimmune diseases selected from the group consisting of: diabetes mellitus, psoriasis, multiple sclerosis, viral eye disease, asthma, asthmatic bronchitis, and arthritis; which comprises administering an effective amount of the composition defined in claim 14.
Claim 34
Dependent Claim
45 words
A method for the treatment of one or more virus-induced and autoimmune diseases selected from the group consisting of: diabetes mellitus, psoriasis, multiple sclerosis, viral eye disease, asthma, asthmatic bronchitis, and arthritis; which comprises administering an effective amount of the composition defined in claim 15.
Claim 35
Dependent Claim
45 words
A method for the treatment of one or more virus-induced and autoimmune diseases selected from the group consisting of: diabetes mellitus, psoriasis, multiple sclerosis, viral eye disease, asthma, asthmatic bronchitis, and arthritis; which comprises administering an effective amount of the composition defined in claim 16.
Claim 36
Dependent Claim
45 words
A method for the treatment of one or more virus-induced and autoimmune diseases selected from the group consisting of: diabetes mellitus, psoriasis, multiple sclerosis, viral eye disease, asthma, asthmatic bronchitis, and arthritis; which comprises administering an effective amount of the composition defined in claim 17.
Claim 37
Dependent Claim
45 words
A method for the treatment of one or more virus-induced and autoimmune diseases selected from the group consisting of: diabetes mellitus, psoriasis, multiple sclerosis, viral eye disease, asthma, asthmatic bronchitis, and arthritis; which comprises administering an effective amount of the composition defined in claim 18.
Claim 38
Dependent Claim
45 words
A method for the treatment of one or more virus-induced and autoimmune diseases selected from the group consisting of: diabetes mellitus, psoriasis, multiple sclerosis, viral eye disease, asthma, asthmatic bronchitis, and arthritis; which comprises administering an effective amount of the composition defined in claim 19.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-10-20 | 1990-04-21 | 1990-10-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-10-20 | 1994-04-21 | 1994-10-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-10-20 | 1998-04-21 | 1998-10-21 | $7700.00 | Window Closed / Lapsed |